{"id":"https://openalex.org/W2012425163","doi":"https://doi.org/10.1185/03007991003672551","title":"Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes","display_name":"Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes","publication_year":2010,"publication_date":"2010-03-03","ids":{"openalex":"https://openalex.org/W2012425163","doi":"https://doi.org/10.1185/03007991003672551","mag":"2012425163","pmid":"https://pubmed.ncbi.nlm.nih.gov/20199137"},"language":"en","primary_location":{"id":"doi:10.1185/03007991003672551","doi":"https://doi.org/10.1185/03007991003672551","is_oa":false,"landing_page_url":"https://doi.org/10.1185/03007991003672551","pdf_url":null,"source":{"id":"https://openalex.org/S206643269","display_name":"Current Medical Research and Opinion","issn_l":"0300-7995","issn":["0300-7995","1473-4877"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Medical Research and Opinion","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5052412166","display_name":"Yutaka Seino","orcid":"https://orcid.org/0000-0002-1099-7989","observed_orcids":["https://orcid.org/0000-0002-1099-7989"]},"institutions":[{"id":"https://openalex.org/I2800996768","display_name":"Kansai Electric Power (Japan)","ror":"https://ror.org/03xrg8731","country_code":"JP","type":"company","lineage":["https://openalex.org/I2800996768"]},{"id":"https://openalex.org/I4210123101","display_name":"Kansai Electric Power Hospital","ror":"https://ror.org/02srt1z47","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210123101"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Y. Seino","raw_affiliation_strings":["Kansai Electric Power Hospital, Osaka, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kansai Electric Power Hospital, Osaka, Japan","institution_ids":["https://openalex.org/I2800996768","https://openalex.org/I4210123101"]}]},{"author_position":"middle","author":{"id":null,"display_name":"M.F. Rasmussen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I189090001","display_name":"Novo Nordisk (Denmark)","ror":"https://ror.org/0435rc536","country_code":"DK","type":"company","lineage":["https://openalex.org/I189090001","https://openalex.org/I2801134892","https://openalex.org/I4210159963"]}],"countries":["DK"],"is_corresponding":false,"raw_author_name":"M.F. Rasmussen","raw_affiliation_strings":["Medical & Science, GLP-1, Novo Nordisk A/S, Bagsvaerd, Denmark"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical & Science, GLP-1, Novo Nordisk A/S, Bagsvaerd, Denmark","institution_ids":["https://openalex.org/I189090001"]}]},{"author_position":"middle","author":{"id":null,"display_name":"T. Nishida","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405265707","display_name":"Novo Nordisk Pharma Ltd. (Japan)","ror":"https://ror.org/05gzvb546","country_code":"JP","type":"company","lineage":["https://openalex.org/I4405265707"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"T. Nishida","raw_affiliation_strings":["Clinical Statistics, Novo Nordisk Pharma Ltd., Tokyo, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Statistics, Novo Nordisk Pharma Ltd., Tokyo, Japan","institution_ids":["https://openalex.org/I4405265707"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5036190568","display_name":"Kohei Kaku","orcid":"https://orcid.org/0000-0003-1574-0565","observed_orcids":["https://orcid.org/0000-0003-1574-0565"]},"institutions":[{"id":"https://openalex.org/I189996419","display_name":"Kawasaki Medical School","ror":"https://ror.org/059z11218","country_code":"JP","type":"education","lineage":["https://openalex.org/I189996419"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"K. Kaku","raw_affiliation_strings":["Internal Medicine, Kawasaki Medical School, Okayama, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Internal Medicine, Kawasaki Medical School, Okayama, Japan","institution_ids":["https://openalex.org/I189996419"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5052412166"],"corresponding_institution_ids":["https://openalex.org/I2800996768","https://openalex.org/I4210123101"],"apc_list":null,"apc_paid":null,"fwci":9.3198,"has_fulltext":false,"cited_by_count":118,"citation_normalized_percentile":{"value":0.98528941,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":93,"max":100},"biblio":{"volume":"26","issue":"5","first_page":"1013","last_page":"1022"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/liraglutide","display_name":"liraglutide","score":0.9929999709129333},{"id":"https://openalex.org/keywords/glibenclamide","display_name":"glibenclamide","score":0.9919999837875366},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9549999833106995},{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.8619999885559082},{"id":"https://openalex.org/keywords/glycemic-control","display_name":"glycemic control","score":0.753000020980835},{"id":"https://openalex.org/keywords/hba1c","display_name":"HbA1c","score":0.953000009059906},{"id":"https://openalex.org/keywords/fasting-blood-glucose","display_name":"fasting blood glucose","score":0.8579999804496765},{"id":"https://openalex.org/keywords/weight-loss","display_name":"weight loss","score":0.6930000185966492},{"id":"https://openalex.org/keywords/hypoglycemia","display_name":"hypoglycemia","score":0.7689999938011169},{"id":"https://openalex.org/keywords/japanese-patients","display_name":"Japanese patients","score":0.6809999942779541},{"id":"https://openalex.org/keywords/non-inferiority","display_name":"non-inferiority","score":0.7049999833106995},{"id":"https://openalex.org/keywords/oral-antidiabetic-drugs","display_name":"oral antidiabetic drugs","score":0.6660000085830688},{"id":"https://openalex.org/keywords/sulfonylureas","display_name":"sulfonylureas","score":0.7009999752044678},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.38199999928474426},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.4909999966621399},{"id":"https://openalex.org/keywords/hba1c-variability","display_name":"HbA1c variability","score":0.3499999940395355}],"concepts":[{"id":"https://openalex.org/C2781308992","wikidata":"https://www.wikidata.org/wiki/Q2526479","display_name":"Liraglutide","level":4,"score":0.991529643535614},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9368982315063477},{"id":"https://openalex.org/C2779768347","wikidata":"https://www.wikidata.org/wiki/Q420626","display_name":"Glibenclamide","level":3,"score":0.9127014875411987},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.6717259287834167},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.6040563583374023},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5617039203643799},{"id":"https://openalex.org/C2910068830","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 Diabetes Mellitus","level":3,"score":0.4664888381958008},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.4118822515010834},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.34626126289367676}],"mesh":[{"descriptor_ui":"D000069450","descriptor_name":"Liraglutide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001786","descriptor_name":"Blood Glucose","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":false},{"descriptor_ui":"D001835","descriptor_name":"Body Weight","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005905","descriptor_name":"Glyburide","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D005905","descriptor_name":"Glyburide","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D005905","descriptor_name":"Glyburide","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006442","descriptor_name":"Glycated Hemoglobin","qualifier_ui":"Q000032","qualifier_name":"analysis","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D008055","descriptor_name":"Lipids","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D010919","descriptor_name":"Placebos","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1185/03007991003672551","doi":"https://doi.org/10.1185/03007991003672551","is_oa":false,"landing_page_url":"https://doi.org/10.1185/03007991003672551","pdf_url":null,"source":{"id":"https://openalex.org/S206643269","display_name":"Current Medical Research and Opinion","issn_l":"0300-7995","issn":["0300-7995","1473-4877"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Medical Research and Opinion","raw_type":"journal-article"},{"id":"pmid:20199137","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/20199137","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current medical research and opinion","raw_type":"Clinical Trial, Phase III"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320322436","display_name":"Novo Nordisk","ror":"https://ror.org/0435rc536"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":18,"referenced_works":["https://openalex.org/W99879799","https://openalex.org/W113756657","https://openalex.org/W577818811","https://openalex.org/W1965377164","https://openalex.org/W1986550531","https://openalex.org/W1988031087","https://openalex.org/W2011486475","https://openalex.org/W2043092889","https://openalex.org/W2067710447","https://openalex.org/W2068488844","https://openalex.org/W2071075324","https://openalex.org/W2093545531","https://openalex.org/W2098129957","https://openalex.org/W2098459806","https://openalex.org/W2103525547","https://openalex.org/W2145924144","https://openalex.org/W2167421636","https://openalex.org/W4213243604"],"related_works":["https://openalex.org/W2043092889","https://openalex.org/W1483095253","https://openalex.org/W2098905490","https://openalex.org/W2312778649","https://openalex.org/W1987538170","https://openalex.org/W1951367122","https://openalex.org/W2325198396","https://openalex.org/W1906367066","https://openalex.org/W2034886580","https://openalex.org/W2057135960"],"abstract_inverted_index":{"OBJECTIVE:":[0],"Liraglutide":[1,112,317],"is":[2],"a":[3,47,116,133,229,245,346,355],"once-daily":[4],"human":[5],"glucagon-like":[6],"peptide-1":[7],"(GLP-1)":[8],"analogue":[9],"developed":[10],"for":[11,322],"the":[12,64,370],"treatment":[13,290],"of":[14,31,50,68,95,120,137,165,231,241,247,267,350,358,374],"type":[15],"2":[16,22],"diabetes":[17],"mellitus":[18],"(T2DM).":[19],"In":[20],"Phase":[21,24,53],"and":[23,42,66,70,172,281,303,342,345],"3":[25],"trials,":[26],"largely":[27],"conducted":[28],"in":[29,73,234,288,325,366,377],"populations":[30],"European":[32],"descent,":[33],"liraglutide":[34,69,103,155,171,200,274,337,375],"has":[35],"been":[36],"shown":[37],"to":[38,102,158,182,217,258,368],"lower":[39,198,265,348],"HbA(1C),":[40],"weight":[41,239,343],"systolic":[43],"blood":[44],"pressure":[45],"with":[46,76,80,154,160,170,175,199,238,250,273,276,328,334,379],"low":[48],"risk":[49],"hypoglycaemia.":[51,351],"This":[52],"3,":[54],"24-week,":[55],"multi-centre,":[56],"double-blind,":[57],"double":[58],"dummy,":[59],"randomised":[60,100],"parallel-group":[61],"trial":[62],"compared":[63,237,275],"efficacy":[65,373],"safety":[67],"glibenclamide":[71,108,176,207,251,277,335],"monotherapy":[72,376],"Japanese":[74,97,326,361],"subjects":[75,98,327],"T2DM,":[77,329],"inadequately":[78],"controlled":[79],"diet":[81],"therapy":[82],"or":[83,107,129,141],"oral":[84],"antidiabetic":[85],"drug":[86],"(OAD)":[87],"monotherapy.":[88],"RESEARCH":[89],"DESIGN":[90],"AND":[91],"METHODS:":[92],"A":[93,263],"total":[94],"411":[96],"were":[99,196,286,297],"2:1":[101],"(n":[104,109],"=":[105,110],"272)":[106],"139).":[111],"was":[113,126,156,223,271,310,330],"administered":[114,127,319],"at":[115,132,162,193],"maximum":[117,135],"planned":[118,134],"dose":[119,136],"0.9":[121],"mg":[122],"once":[123,128,320],"daily.":[124],"Glibenclamide":[125],"twice":[130],"daily":[131,321],"2.5":[138],"mg/day,":[139],"before":[140],"after":[142],"meals.":[143],"CLINICAL":[144],"TRIAL":[145],"REGISTRATION:":[146],"NCT00393718.":[147],"RESULTS:":[148],"After":[149],"24":[150,163,194,323],"weeks,":[151],"glycaemic":[152,340],"control":[153,341],"non-inferior/superior":[157],"glibenclamide,":[159,301,307,314],"HbA(1C)":[161],"weeks":[164,195,324],"6.99%":[166],"(SE":[167],"+/-":[168,204],"0.07)":[169],"7.50%":[173],"(+/-0.09)":[174],"(difference,":[177,252],"-0.5%;":[178],"95%":[179,214,255],"CI":[180,215,256],"-0.70":[181],"0.30;":[183],"p":[184,219,260],"<":[185,220,261,279],"0.0001).":[186,221,262],"Mean":[187],"fasting":[188],"plasma":[189],"glucose":[190],"(FPG)":[191],"levels":[192],"significantly":[197,264,347],"(7.6":[201],"mmol/l":[202,209],"[SE":[203],"0.1])":[205],"vs":[206],"(8.3":[208],"[+/-0.1];":[210],"difference,":[211],"-0.72":[212],"mmol/l;":[213],"-1.0":[216],"-0.4;":[218],"Weight":[222],"reduced":[224],"by":[225],"-0.92":[226],"kg":[227,233,243,249],"from":[228,244],"baseline":[230,246],"65.2":[232],"liraglutide-treated":[235],"patients,":[236,362],"gain":[240],"+0.99":[242],"64.8":[248],"-1.91":[253],"kg;":[254],"-2.34":[257],"-1.48;":[259],"rate":[266],"minor":[268],"hypoglycaemic":[269,284],"episodes":[270,285],"achieved":[272,338],"(p":[278],"0.0001),":[280],"no":[282],"major":[283],"reported":[287],"either":[289],"group.":[291],"The":[292],"most":[293],"common":[294],"gastrointestinal":[295],"AEs":[296],"diarrhoea":[298],"(liraglutide,":[299,305,312],"6.3%;":[300],"3.8%)":[302],"constipation":[304],"5.6%;":[306],"3.8%).":[308],"Nausea":[309],"infrequent":[311],"4.5%;":[313],"1.5%).":[315],"CONCLUSIONS:":[316],"monotherapy,":[318,336],"well":[331],"tolerated.":[332],"Compared":[333],"superior":[339],"outcome,":[344],"incidence":[349],"Future":[352],"studies,":[353],"comprising":[354],"greater":[356],"proportion":[357],"true":[359,371],"therapy-na\u00efve":[360],"will":[363],"be":[364],"beneficial":[365],"order":[367],"establish":[369],"add-on":[372],"patients":[378],"T2DM.":[380]},"counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":4},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":7},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":6},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":7},{"year":2016,"cited_by_count":6},{"year":2015,"cited_by_count":14},{"year":2014,"cited_by_count":15},{"year":2013,"cited_by_count":14},{"year":2012,"cited_by_count":12}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2016-06-24T00:00:00"}